Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pramipexole vs Escitalopram for MDD and MND in HIV
NCT06705478Phase 2Suspended
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of pramipexole in major depressive disorder (MDD), mild neurocognitive disorder, sponsored by National Institute of Allergy and Infectious Diseases. Started May 2026; status: suspended.
02
Drugs
pramipexole
03
Conditions
major depressive disorder (MDD)mild neurocognitive disorder
Beyond the preview
Go deeper on NCT06705478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06705478.